Floatz logo

Donanemab

Amyloid Beta Protein

Michael Rafii, MD, PhDmonoclonal_antibodyPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Amyloid Beta Protein cohort.

Asset / SponsorPhaseRating
Aci-24.060
AC Immune SA
Phase 1/2NR

Same molecule, other indications

Donanemab is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
70 / 100
View asset →
Down syndromeDormant
BB
Indicative ·
65 / 100
View asset →
central nervous system disorderDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →